However, it is difficult to predict the exact level of product sales and royalties fof a strongly growing product for the whole year. In addition, the EUR 70 million Nubeqa®-related milestone is expected to increase the net sales of the Innovative Medicines business division. The net sales of the business division increases also due to the EUR 60 million item to be released from the balance sheet in Q3 2024. The Branded Products and Animal Health business divisions are also estimated to improve their net sales in 2024.